According to a recent market study published by Growth Market Reports, titled, “Global Synthetic Human Secretin Market – by type, by end-user, and by regions: Size, Share, Trends and Opportunity Analysis, 2018-2028”, the market was valued at US$ 8.4 Million in 2020 and is expected to grow at a moderate growth rate of 5.6% by the year 2028. Rising diagnostic testing for pancreatic disorders increased disposable income, and the rising prevalence of pancreatic disorders is expected to drive market growth during the forecast period.

Request a free sample copy @ https://growthmarketreports.com/request-sample/3996

Synthetic secretin is a pure peptide hormone that has the same amino acid sequence as naturally occurring secretin. It is known as a ChiRhoStim and human secretin. Synthetic human secretin is a laboratory-created form of secretin. Secretin stimulates the pancreas, liver, and stomach to release digestive enzymes to help digest food.

ChiRhoStim (human secretin for injection) has been approved for the diagnosis of exocrine pancreas function testing, and the Zollinger-Ellison Syndrome test. Synthetic secretin is administered intravenously. It is used for the diagnosis of pancreatic dysfunction or gastrinoma. Currently, synthetic secretin is used to diagnose prevalent pancreatic cancer disorders and chronic pancreatitis.

Pancreatic diseases such as acute pancreatitis, chronic pancreatitis, pancreatic cancer, cystic fibrosis, and others are becoming more common in humans worldwide. The FDA provides regulatory and scientific information about drug approval information. Pancreatic cancer is expected to be diagnosed in an estimated 60,430 adults in the US this year.

About 3% of all cancers are caused by this disease. Pancreatic cancer is the eighth most common type of cancer in women and the tenth most common type of cancer in men. Since 2000, the annual incidence of pancreatic cancer increased by about 1%. In combination with the World Health Organization, the Center for Disease Control and Prevention developed hospital-based, practical, guidelines.

The manual is used in these guidelines to assist healthcare facilities in diagnosing pancreatic injury and disease cases and prevent further hospitalizations by utilizing locally available resources and less financial resources. Some organizations and associations, including the National Institutes of Health (NIH), Johns Hopkins University, Columbia University, and others, are focusing on the clinical trial of synthetic human secretin for diagnosis, particularly in pancreatic disorders.

The clinical trials follow the US and international Good Clinical Practice standards (GCP) (FDA Title 21 Part 312 and International Conference on Harmonization guidelines), relevant government regulations, and institutional research policies and procedures. Regulations for synthetic human secretin products are proposed to protect the health, safety, and welfare of people in and for the environment. These regulations are intended to protect the health of people, protect and improve the environment, and encourage sustainable development.

FDA set some regulations regarding the production, distribution, and use of products. These rules are set to standardize the manufacture and sales of products around the globe. Few important associations and industry bodies include World Health Organization (WHO), Food Drug Administration (FDA), European Union (EU), American Pancreatic Association (APA), National Pancreas Foundation (NPF), American Cancer Society (ACS), National Cancer Institute, American Gastroenterological Association (AGA), European Medicines Agency (EMA), and others.

For instance, ChiRhoClin declared that the Food and Drug Administration (FDA) approved several labeling updates for ChiRhoStim (human secretin for injection) and other products. The global Synthetic Human Secretin market is consolidated based on type, end-user, and regions. On the basis of type, the synthetic human secretin market is segregated into exocrine pancreas function testing and Zollinger – Ellison Syndrome Testing.

The exocrine pancreas function testing segment held a significant share of the market. This test includes direct and indirect tests. Indirect tests are fueling the market, due to the availability of these tests in clinical settings. Based on end-users, the market is segregated into Academics /Hospitals and clinics. The Academics /Hospital segment held a significant share of the market owing to the advancements in diagnosis technology and growing hospitalization of patients with pancreatic diseases and cancer, and gastrointestinal disorders.

Based on regions the Global Synthetic Human Secretin market has been fragmented into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to grow at a rapid pace due to the rising prevalence of pancreatitis, & pancreatic cancer, and acute pancreatitis (AP) in the US, which is a leading cause of pancreatic disorders.

Europe accounts for a considerable share of the market, due to the prevalence of pancreatitis in Eastern & Central Europe. The Asia Pacific is estimated to account for a significant share of the market. India, Japan, and China are likely to account for the key share owing to rising disposable income and the prevalence of pancreatic cancer.

The Synthetic Human Secretin market is projected to witness a slight decrease in year-on-year growth for 2020 as compared to the previous year 2019. Regulatory bodies anticipated to play a key role in boosting the market are supporting the growth of the market in 2020. The Synthetic Human Secretin market is growing at a significant pace due to the rising pharmaceuticals and medical diagnostic industry which is expected to fuel the market.

As per Growth Market Reports industry analyst Sumitra Choudhary “The global Synthetic Human Secretin market is anticipated to witness moderate growth during the forecast period 2020-2027. The Synthetic Human Secretin market is registering growth opportunities across the globe, government initiatives towards improving healthcare infrastructure & facilities and increasing demand for various supportive care. In addition, increasing technological advancements and pipelines of synthetic drugs across the globe”.

The first quarter of 2020 was an unforeseen turning point for the Synthetic Human Secretin market. Supply chains were disturbed by COVID-19 outbreaks in major regions, thus reducing the demand for various products, due to uncertainty in the global economy. Certain discrepancies in production and supply chain created mild disruptions across some areas in the supply chain of the Synthetic Human Secretin market.

However, after the second quadrant increasing product demand for industries has boosted the market growth in 2020. The increasing production process in the biological industry and increasing concern for health safety in multiple organizations boosted the Synthetic Human Secretin market in 2020. Many pharmaceutical companies are being forced to temporarily close, lay off staff, or shift to remote operations.

Many clinical trials were suddenly halted, due to the pandemic. Numerous cases of pancreatic injury and acute pancreatitis (AP) were reported with the novel coronavirus infections patients. Moreover, FDA-approved diagnosis drugs are available in the market for the diagnosis of pancreatic disorders.

Key Takeaways from the Study

  • The players include BCN Peptides, Bio-Techne, ChiRhoClin, Inc., CPC Scientific Inc., Hexonsynth, Prospec-Tany Technogene Ltd. among others hold a significant share of the Global Synthetic Human Secretin market in the year 2020.
  • The market in North America held a significant share of the market, owing to the rising prevalence of Pancreatitis, which affects around 80,000 people in the US each year. Two main types of pancreatitis are acute and chronic. About 90% of all cases that occur are acute pancreatitis, while 10% of the cases are chronic pancreatitis. The risk of pancreatic cancer is growing in patients with chronic pancreatitis, especially hereditary pancreatitis, due to factors such as changing diet and lifestyle, alcohol use and smoking in this region. This is expected to boost the market in the future.
  • In terms of type, The Exocrine Pancreas Function Testing segment is expected to grow in the forecast period, owing to pancreatic diseases, the secretin test types include direct and indirect tests that are commonly used. Secretin is injected intravenously (IV) for this test to measure the response to secretin. Indirect tests are simple to perform and appear to be as effective as the secretin test in detecting pancreatic exocrine insufficiency. Indirect tests are becoming in the market, as it is available in clinical settings.
  • The Academics /Hospital segment held a significant share of the market. owing to advancements in diagnosis technology and increasing government initiatives to establish healthcare infrastructure, hence hospitals are major providers of this diagnostic testing. Growing hospitalization of patients with pancreatic diseases, pancreatic cancer, and gastrointestinal disorders, is expected to drive hospital demand for synthetic human secretin.

Report Scope

Report Metric

Details

Market Value in 2020

US$ 8.4 Million

Market Growth Rate (from 2020 to 2028)

5.6%

Historical Data

2018, & 2019

Base Year

2020

Forecast Period

2021 – 2028

Units Considered

Value (US$ Million)

Market Segments

Type, End-user, and Regions

Regional Scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Companies Profiled

BCN Peptides, Bio-Techne, ChiRhoClin, Inc., CPC Scientific Inc., Hexonsynth, Prospec-Tany Technogene Ltd., LifeTein LLC., Abcam plc., Abcepta, Creative BioMart, Merck KGaA, GenScript

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

Target Audience

  • Supply-side: Manufacturers, raw material suppliers, and distributors
  • Demand Side: Hospitals/Clinics, Biotech and Pharmaceutical Industry, Academic and research institutes, Patients, and Others
  • Regulatory Side: World Health Organization (WHO), Food Drug Administration (FDA), European Union (EU), American Pancreatic Association (APA), National Pancreas Foundation (NPF), American Cancer Society (ACS), National Cancer Institute, American Gastroenterological Association (AGA), European Medicines Agency (EMA), and others